Stocktoria
TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA
NYSE · stock · Pharmaceutical Preparations · website · IPO 1951-01-01
TEVA PHARMACEUTICAL INDUSTRIES LTD financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.3B | $16.5B | $15.8B | $14.9B | $15.9B | $16.7B | $16.9B | $18.3B | $22.4B | $21.9B |
| Gross profit | $8.9B | $8.1B | $7.6B | $7.0B | $7.6B | $7.7B | $7.5B | $8.3B | $10.6B | $11.7B |
| R&D expense | — | — | — | $98.0M | — | — | — | $114.0M | $175.0M | $422.0M |
| Operating income | $2.2B | -$303.0M | $433.0M | -$2.2B | $1.7B | -$3.6B | -$443.0M | -$1.6B | -$17.5B | $2.2B |
| Interest expense | $916.0M | $1.0B | $1.0B | $930.0M | $891.0M | $901.0M | $822.0M | $920.0M | $875.0M | $546.0M |
| Income tax | -$180.0M | $676.0M | -$7.0M | -$643.0M | $211.0M | -$168.0M | -$278.0M | -$195.0M | -$1.9B | $521.0M |
| Net income | $1.4B | -$1.6B | -$559.0M | -$2.4B | $417.0M | -$4.0B | -$999.0M | -$2.1B | -$16.3B | $329.0M |
| EPS (diluted) | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.91 | $-2.35 | $-16.26 | $0.07 |
| Operating cash flow | $1.6B | $1.2B | $1.4B | $1.6B | $798.0M | $1.2B | $748.0M | $2.4B | $2.2B | $3.9B |
| Free cash flow | — | — | — | $1.0B | $236.0M | $638.0M | $223.0M | $1.8B | $1.4B | $3.0B |
| Cash & equivalents | $3.6B | $3.3B | $3.2B | $2.8B | $2.2B | $2.2B | $2.0B | $1.8B | $963.0M | $988.0M |
| Inventory | $3.2B | $3.0B | $4.0B | $3.8B | $3.8B | $4.4B | $4.4B | $4.7B | $4.9B | $5.0B |
| Total assets | $40.7B | $39.3B | $43.5B | $44.0B | $47.7B | $50.6B | $57.5B | $60.7B | $70.6B | $93.1B |
| Total liabilities | $32.8B | $33.6B | $35.4B | $35.4B | $36.4B | $39.6B | $42.4B | $44.9B | $51.9B | $58.1B |
| Shareholders' equity | $7.9B | $5.4B | $8.1B | $8.6B | $11.2B | $11.1B | $15.1B | $15.8B | $18.7B | $35.0B |
Growth · year-over-year · Revenue CAGR -2.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +4.3% | +4.4% | +6.2% | -6.0% | -4.7% | -1.4% | -7.6% | -18.4% | +2.2% | +11.5% |
| Net income growth | — | — | — | -686.6% | — | — | — | — | -5043.8% | -79.3% |
| EPS growth | — | — | — | -678.9% | — | — | — | — | -23328.6% | -96.2% |
| Free cash flow growth | — | — | — | +341.5% | -63.0% | +186.1% | -87.6% | +32.9% | -54.8% | -37.3% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.